



JC06 Rec'd PCT/PTO 12 SEP 2005

PCT
#5IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:

Applicant(s): Grummt, et al.

Application No.: 10/539,473

Filing Date: 20 June 2005

**INACTIVE TRANSCRIPTION
FACTOR TIF-IA AND USES
THEREOF**

) Docket No.: 4121-177
) Examiner: Not Yet Assigned
) Art Unit: Not Yet Assigned
) Customer No.: 23448
) 23448

FIRST CLASS MAIL CERTIFICATE

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, and First Class Mailed under the provisions of 37 CFR 1.8.

_____
September 9, 2005_____
Date of Mailing

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.


2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- c. Attached is our check no. _____ in the amount of \$_____ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check no. _____ in the amount of \$180.00 in payment of the petition fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,



Marianne Fuerer
Reg. No. 39,983
Attorney for Applicant

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
Telephone: (919) 419-9350
Fax: (919) 419-9354
Attorney Ref: 4121-177



PTO/SB/08A (01-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 1

COMPLETE IF KNOWN

Application Number	10/539,473
Filing Date	June 20, 2005
First Named Inventor	GRUMMT, et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4121-177

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
	AA	WO 00/55316	09-21-2000	Grummt, et al.	X <input type="checkbox"/>

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AB	XP-002143820: Moorefield, et al., "RNA polymerase I transcription factor Rrn3 is functionally conserved between yeast and human", PNAS, pp. 4724-4729 (April 25, 2000).	
	AC	XP-002238556: Yuan, et al., "Multiple interactions between RNA polymerase I, TIF-IA and TAF ₁ subunits regulate preinitiation complex assembly at the ribosomal gene promoter", EMBO reports, vol.3, no. 11, pp. 1082-1087 (2002).	
	AD	XP-002238557: Cavanaugh, et al., "Rrn3 Phosphorylation is a regulatory checkpoint for Ribosome Biogenesis", Journal of Biological Chemistry, pp. 27423-27432 (May 2, 2002).	
	AE	XP-002228558: Zhao, et al., "ERK-Dependent Phosphorylation of the Transcription Initiation Factor TIF-IA is Required for RNA Polymerase I Transcription and Cell Growth", Molecular Cell, Vol. 11, 405-413, (February 2003).	

Examiner signature		Date Considered
--------------------	--	-----------------

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

¹ All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).